Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

Organon’s workforce cuts come several months after the company’s loss of exclusivity to its second-largest product, Atozet.

Marine Le Pen’s election ban risks a surge in anti-establishment sentiment in France that could undermine efforts to stabilize the nation’s creaky public finances.

Organon (OGN) stock in focus as the Merck (MRK) spinoff buys rights to Biogen's (BIIB) biosimilar Tofidence, targeting ...

New Jersey Democratic Sen. Cory Booker has carried an all-night speech in protest of President Donald Trump’s agenda into a ...

Tofidence is indicated in certain patients for the treatment of moderate to severe rheumatoid arthritis, giant cell arteritis ...

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week's most newsworthy and ...

2025 88 Investing.com -- The S&P 500 closed higher Tuesday after swinging between gains and losses as investors weighed another slump in consumer confidence and an Tesla-led rally in tech.

Organon (OGN) closed the latest trading day at $15.39, indicating a -1.35% change from the previous session's end. The stock's performance was behind the S&P 500's daily gain of 0.08%. Elsewhere ...